Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions. The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology. Read More
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for small-cap stocks, has notably outperformed the tech-heavy S&P 500 and the Nasdaq Composite. This early-January
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a long period of living in the shadow of "Magnificent Seven" mega-caps, smaller domestic companies are finally
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P 500 (INDEXSP: .INX) is finishing the year near the psychological 7,000 mark, a milestone that
EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.
